Fosun Pharma Selects Medidata’s Unified Platform for Clinical Development in China
August 16 2017 - 8:00PM
Business Wire
Leading Chinese Healthcare Group Adopts
Medidata’s Cloud Technology to Bring Operational Efficiencies to
its R&D Programs
Medidata (NASDAQ: MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced an enterprise agreement with leading Chinese
healthcare group, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s
subsidiary Shanghai Fosun Pharmaceutical Development Co.,
Ltd.(Fosun Pharma). Fosun Pharma has adopted the Medidata Clinical
Cloud® platform to improve data management capabilities and bring
operational efficiencies to its clinical studies in China.
Fosun Pharma is implementing Medidata Rave®, a unified EDC and
CDMS solution for capturing, managing and reporting patient data,
across its generics development pipeline, accelerating treatments
in such therapeutic areas as cardiovascular, oncology,
anti-infection and central nervous system (CNS). The leading
Chinese clinical R&D company is also leveraging Rave Study
Design and Build Essentials (SDBE) training. Taught on RaveX—the
latest version of Rave—SDBE will equip Fosun Pharma’s study teams
with the fundamentals required to develop and update electronic
Case Report Forms (eCRFs), ultimately optimizing study
implementation and ensuring trail timelines are met.
“We are proud to be Fosun Pharma’s cloud-based, clinical
technology platform of choice and a key addition to its roster of
partners,” said Edwin Ng, Medidata’s vice president of field
operations, APeJ (Asia Pacific except Japan). “We look forward to
powering Fosun Pharma’s clinical studies with Medidata’s flexible,
cutting-edge technology as they strive to become a first-class
enterprise in the global healthcare market and a key player in the
bioequivalence space.”
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170816006052/en/
MedidataInvestor:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Medidata
SolutionsErik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024